News & Events

Meet selectION Inc. at Biocom’s 10th Annual Global Life Science Partnering Conference in San Diego on February 25^th to 27^th, 2020

January 9, 2020

SAN DIEGO, January 9, 2020 – Meet Antonius Schuh, Ph.D. (CEO) and Andreas Klostermann, Ph.D. (CSO) for an update on selectION’s best-in-class ion channel blockers and the status of the…

selectION, Inc. Announces $4.1M Series A Investment

May 31, 2019

News

SAN DIEGO, May 31, 2019 – selectION, Inc., a biotherapeutic company focused on the development of peptide ion channel blockers with class leading selectivity, announced today it has received a…

selectION, Inc. Strengthens Scientific Advisory Team with the Appointment of Fred Ramsdell, Ph.D. & Mark Benedyk, Ph.D. as Strategic Advisors and Members of the Scientific Advisory Board

November 30, 2018

News

SAN DIEGO, November 30, 2018 – selectION, Inc. a biotechnology company that has established an efficient technology platform to develop novel peptide therapies incorporating highly selective peptide blockers for ion…

selectION, Inc. Strengthens its Leadership and Scientific Team with the Appointment of Cam Gallagher to its Board of Directors & Dr. Christopher Larson, Ph.D. as Strategic Advisor and Member of the Scientific Advisory Board

August 29, 2018

News

SAN DIEGO, August 29, 2018 – selectION, Inc. a biotechnology company that has established an efficient technology platform to develop novel peptide therapies incorporating highly selective peptide blockers for ion…

selectION appoints Antonius Schuh as new CEO

May 3, 2018

News

Dr. Schuh has over 20 years of executive leadership experience in the biotechnology, healthcare and life sciences industries and has served as CEO of five life sciences companies, including Arcturus…

Meet selectION Inc. at this years Biocom Global Life Science Partnering Conference in San Diego on February 28th

February 21, 2018

Events

Andreas Klosterman, Ph.D. (CEO) will give an update on selectION’s best-in-class ion channel antagonists and discuss the principles of the company’s systematical peptide design to obtain the most selective and specific ion channel blockers.

News & Events

Meet selectION Inc. at Biocom’s 10th Annual Global Life Science Partnering Conference in San Diego on February 25^th to 27^th, 2020

selectION, Inc. Announces $4.1M Series A Investment

selectION, Inc. Strengthens Scientific Advisory Team with the Appointment of Fred Ramsdell, Ph.D. & Mark Benedyk, Ph.D. as Strategic Advisors and Members of the Scientific Advisory Board

selectION, Inc. Strengthens its Leadership and Scientific Team with the Appointment of Cam Gallagher to its Board of Directors & Dr. Christopher Larson, Ph.D. as Strategic Advisor and Member of the Scientific Advisory Board

selectION appoints Antonius Schuh as new CEO

Meet selectION Inc. at this years Biocom Global Life Science Partnering Conference in San Diego on February 28th

Site Search

News Categories

Recent News

About

Recent News

Contact

News & Events

Meet selectION Inc. at Biocom’s 10th Annual Global Life Science Partnering Conference in San Diego on February 25th to 27th, 2020

selectION, Inc. Announces $4.1M Series A Investment

selectION, Inc. Strengthens Scientific Advisory Team with the Appointment of Fred Ramsdell, Ph.D. & Mark Benedyk, Ph.D. as Strategic Advisors and Members of the Scientific Advisory Board

selectION, Inc. Strengthens its Leadership and Scientific Team with the Appointment of Cam Gallagher to its Board of Directors & Dr. Christopher Larson, Ph.D. as Strategic Advisor and Member of the Scientific Advisory Board

selectION appoints Antonius Schuh as new CEO

Meet selectION Inc. at this years Biocom Global Life Science Partnering Conference in San Diego on February 28th

Site Search

News Categories

Recent News

About

Recent News

Contact

Meet selectION Inc. at Biocom’s 10th Annual Global Life Science Partnering Conference in San Diego on February 25^th to 27^th, 2020